Journal of Cachexia, Sarcopenia and Muscle最新文献

{"title":"The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review","authors":"Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, Pratik Choudhary, Emma L. Watson","doi":"10.1002/jcsm.13677","DOIUrl":"https://doi.org/10.1002/jcsm.13677","url":null,"abstract":"BackgroundObesity is a chronic disease associated with increased risk of multiple metabolic and mental health–related comorbidities. Recent advances in obesity pharmacotherapy, particularly with glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs), have the potential to transform obesity and type 2 diabetes mellitus (T2DM) care by promoting marked weight loss, improving glycaemic control and addressing multiple obesity‐related comorbidities, with added cardio‐renal benefits. Dual agonists combining GLP‐1 with other enteropancreatic hormones such as glucose‐dependent insulinotropic polypeptide (GIP) have also been developed in recent years, leading to greater weight loss than using GLP‐1 RAs alone. However, up to 40% of the weight lost with GLP‐1 RAs comes from lean body mass, raising concerns about potential adverse effects on skeletal muscle function. Mitochondrial dysfunction, characterized by reduced mitochondrial size and activity, is prevalent in individuals with obesity and T2DM and is a known contributor to muscle wasting in ageing and some chronic diseases. This systematic review investigates the impact of GLP‐1‐based therapies on skeletal muscle mitochondrial function in individuals with obesity and T2DM or in related animal and cell models.MethodsA comprehensive search of MEDLINE, Scopus, CINAHL and <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">clinicaltrials.gov</jats:ext-link> was conducted. Inclusion criteria included randomized controlled trials, randomized crossover trials, cluster randomized control trials and basic science studies involving any GLP‐1 RA or GLP‐1/GIP dual agonist. Outcomes of interest were skeletal muscle respiratory function either in the form of measurements of mass, number, content, oxidative capacity/respiratory function, mitochondrial dynamics, mitochondrial biogenesis and mitophagy.ResultsEight studies were eligible for analysis; no human studies were identified. All of the included studies used GLP‐1 RAs (single agonists) as intervention. The emerging evidence suggests that GLP‐1 RAs increase mitochondrial area, number and morphology (i.e., reduces swelling). Data are conflicting on the effect of GLP‐1 RAs upon mitochondrial mass, respiration and the expression of uncoupling proteins and PGC‐1α. Data also demonstrate muscle specific (i.e., soleus vs. extensor digitorum longus) responses to GLP‐1 RAs.ConclusionGLP‐1 RAs appear to have a positive effect upon mitochondria area, number and morphology, but effects upon other aspects of mitochondrial health remain inconclusive. Data are very limited and solely presented in animal and in vitro models. Future studies should be conducted in human populations in order to begin to understand the effect of GLP‐1 RAs and GLP‐1‐based therapies on human skeletal muscle mitochondria.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"64 17 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients","authors":"Steven D. Tran, Noah J. Forrest, Vijeeth Guggilla, Geovanni M. Perottino, Jodi L. Johnson, Jeffrey Sosman, Ishan Roy, Theresa L. Walunas","doi":"10.1002/jcsm.13685","DOIUrl":"https://doi.org/10.1002/jcsm.13685","url":null,"abstract":"Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and disability-free, hospitalization-free and overall survival of cancer patients.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"106 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer","authors":"Daria Neyroud, Andrew C. D'Lugos, Enrique J. Trevino, Chandler S. Callaway, Jacqueline Lamm, Orlando Laitano, Brittney Poole, Michael R. Deyhle, Justina Brantley, Lam Le, Andrew R. Judge, Sarah M. Judge","doi":"10.1002/jcsm.13668","DOIUrl":"https://doi.org/10.1002/jcsm.13668","url":null,"abstract":"Cancer cachexia represents a debilitating muscle wasting condition that is highly prevalent in gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC). Cachexia is estimated to contribute to ~30% of cancer-related deaths, with deterioration of respiratory muscles suspected to be a key contributor to cachexia-associated morbidity and mortality. In recent studies, we identified fibrotic remodelling of respiratory accessory muscles as a key feature of human PDAC cachexia.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"26 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142981659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Value of Sarcopenia in Clinical Outcomes in Cervical Cancer: A Systematic Review and Meta-Analysis","authors":"Fang Wang, Hongnan Zhen, Kang Yu, Pengju Liu","doi":"10.1002/jcsm.13674","DOIUrl":"https://doi.org/10.1002/jcsm.13674","url":null,"abstract":"Sarcopenia is a condition characterized by inadequate muscle and function decline and is often associated with ageing and cancer. It is established that sarcopenia and muscle loss occurred during treatment are associated with the clinical outcomes of patients with cancer. This systematic review and meta-analysis aims to evaluate the association between sarcopenia at pretreatment and during treatment and overall survival or disease progression in patients with cervical cancer.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"7 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ergogenic Benefits of β‐Hydroxy‐β‐Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta‐Analyses","authors":"Mohammad Vesal Bideshki, Mehrdad Behzadi, Mehrdad Jamali, Parsa Jamilian, Meysam Zarezadeh, Bahram Pourghassem Gargari","doi":"10.1002/jcsm.13671","DOIUrl":"https://doi.org/10.1002/jcsm.13671","url":null,"abstract":"Backgroundβ‐Hydroxy‐β‐methyl butyrate (HMB) is a metabolite of the amino acid leucine, known for its ergogenic effects on body composition and strength. Despite these benefits, the magnitude of these effects remains unclear due to variability among studies. This umbrella review aims to synthesize meta‐analyses investigating the effects of HMB on body composition and muscle strength in adults.MethodsA comprehensive literature search was conducted in Scopus, PubMed and Web of Science without date or language restrictions until August 2024. The study protocol was registered at Prospero (No. CRD42023402740). Included studies evaluated the effects of HMB supplementation on body mass, fat mass (FM), fat‐free mass (FFM), muscle mass and performance outcomes. Effect sizes (ESs) and 95% confidence intervals (CIs) were calculated, and a random‐effects model was used for meta‐analysis. Standard methods assessed heterogeneity, sensitivity and publication bias. The methodological quality of included studies was assessed using the AMSTAR2 tool.ResultsEleven studies comprising 41 data sets were included, with participants aged 23–79 years. HMB supplementation significantly increased muscle mass (ES: 0.21; 95% CI: 0.06–0.35; <jats:italic>p</jats:italic> = 0.004), muscle strength index (ES: 0.27; 95% CI: 0.19–0.35; <jats:italic>p</jats:italic> &lt; 0.001) and FFM (ES: 0.22; 95% CI: 0.11–0.34; <jats:italic>p</jats:italic> &lt; 0.001). No significant changes were observed in FM (ES: 0.03; 95% CI: −0.04 to 0.35; <jats:italic>p</jats:italic> = 0.09) or body mass (ES: 0.09; 95% CI: −0.06 to 0.24; <jats:italic>p</jats:italic> = 0.22). The quality assessment revealed that five studies were of high quality, three were of low quality and three were of critically low quality.ConclusionsHMB supplementation may benefit individuals experiencing muscular atrophy due to physiological conditions, particularly enhancing muscle mass and strength without significant changes in fat mass or body weight.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"95 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging","authors":"Chhanda Bose, Judit Megyesi, Oleg Karaduta, Sharda P. Singh, Sundararaman Swaminathan, Sudhir V. Shah","doi":"10.1002/jcsm.13678","DOIUrl":"https://doi.org/10.1002/jcsm.13678","url":null,"abstract":"BackgroundA decline in skeletal muscle mass and function known as skeletal muscle sarcopenia is an inevitable consequence of aging. Sarcopenia is a major cause of decreased muscle strength, physical frailty and increased muscle fatigability, contributing significantly to an increased risk of physical disability and functional dependence among the elderly. There remains a significant need for a novel therapy that can improve sarcopenia and related problems in aging. Iron accumulation, especially catalytic iron (labile iron) through increased oxidative stress, could be one of the contributing factors to sarcopenia. Our study aimed to examine the effect of an iron chelator on age‐related sarcopenia in mice.MethodsWe investigated the effect of iron chelation (deferiprone, DFP) in sarcopenia, using mice with klotho deficiency (&lt;jats:italic&gt;kl/kl&lt;/jats:italic&gt;), an established mouse model for aging. Four weeks old Klotho &lt;jats:sup&gt;−/−&lt;/jats:sup&gt; male mice were treated with 25 mg/kg body weight of iron chelator deferiprone in drinking water for 8–14 weeks (&lt;jats:italic&gt;n&lt;/jats:italic&gt; = 12/group, treated and untreated). At the end of the study, gastrocnemius, quadriceps and bicep muscles were dissected and used for western blot and immunohistochemistry analysis, histopathology and iron staining. Serum total iron, catalytic iron and cytokine ELISAs were performed with established methods.ResultsTreatment with DFP significantly reduced loss of muscle mass in gastrocnemius and quadriceps muscles (&lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.0001). Total and catalytic iron content of serum and iron in muscles were significantly (both &lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.0001) lower in the treated animals. The inhibitory factor of myogenesis, the myostatin protein in gastrocnemius muscles (&lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.019) and serum (&lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.003) were downregulated after 8 weeks of therapy accompanied by an increased in muscle contractile protein myosin heavy chain (~2.9 folds, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.0004). Treatment decreased inflammation (serum IL6 and TNFα) (&lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.0001, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.005), respectively, and elevated insulin‐like growth factor levels (&lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.472). This was associated with reduced DNA damage and reduced 8‐hydroxy 2 deoxyguanosine in muscle and HO‐1 protein (&lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.001, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 079), respectively. Significant weight loss (&lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.001) and decreased water intake (&lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.012) were observed in untreated mice compared to treatment group. Kaplan–Meier survival curves show the median life span of treated mice was 108 days as compared to 63 days for untreated mice (&lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.0002).ConclusionsIn summary, our research findings indicate that deferiprone reduced age‐related sarcopenia in the muscles of &lt;jats:italic&gt;Klotho&lt;/","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"36 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Variations in Phenylalanine Concentrations Associate Adverse Cardiac Remodelling in Adult Patients With Phenylketonuria—A Long‐Term CMR Study","authors":"Radu Tanacli, Patrick Doeblin, Alessandro Faragli, Jan‐Hendrik Hassel, Christian Stehning, Ursula Plöckinger, Athanasia Ziagaki, Sebastian Kelle","doi":"10.1002/jcsm.13667","DOIUrl":"https://doi.org/10.1002/jcsm.13667","url":null,"abstract":"BackgroundDespite a phenylalanine (Phe) restrictive diet, most adult patients with ‘classical’ phenylketonuria (PKU) maintain life‐long Phe concentrations above the normal range and receive tyrosine (Tyr) and protein‐enriched diets to maintain acceptable concentrations and ensure normal development. While these interventions are highly successful in preventing adverse neuropsychiatric complications, their long‐ term consequences are incompletely explored. We observed early cardiomyopathic characteristics and associated hemodynamic changes in adult PKU patients and present here the results of a longitudinal evaluation of cardiac phenotype.MethodsFifteen adult patients with PKU (age: 39.8 ± 8.1 years, 9 males and 6 females) underwent a comprehensive follow‐up cardiac magnetic resonance (CMR) imaging assessment after a mean follow‐up interval of 8.3 ± 0.3 years from the initial baseline visit. The CMR protocol included left (LV) and right (RV) ventricular and left atrial (LA) volumetric assessment, LV parametric mapping (precontrast and postcontrast T1 and T2 maps, extracellular volume [ECV]), multilayer LV myocardial strain, systolic and diastolic hemodynamic forces and RV and LA strain and aortic distensibility evaluation. Plasma concentrations of Phe, tyrosine (Tyr) and other biochemical markers of disease were retrospectively collected. For comparison, a group of 20 matched control subjects undergoing an identical CMR protocol was included.ResultsOn average, the LV end‐diastolic volume (EDV) (158 ± 29 vs. 143 ± 29 mL, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.013) and end‐systolic volume (ESV) (68 ± 18 vs. 62 ± 18 mL, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.011) were lower at follow‐up. In contrast, LV mass (LVM) (72 ± 25 vs. 82 ± 29 g, &lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.001) and the ratio LVM/EDV (0.46 ± 0.12 vs. 0.58 ± 0.23 g/mL, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.005) were increased, and T1 times were longer (940 ± 42 vs. 1010 ± 35 ms, &lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.001). LV EF (57 ± 6 vs. 57 ± 7%, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.90), longitudinal (GLS) and circumferential (GCS) systolic strain remained unchanged, but early diastolic hemodynamic (HD) forces were more markedly negative (−19.4 ± 7.0 vs. −26.5 ± 12.2%, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.012), while LA strain 43.8 ± 11.3 vs. 37.3 ± 9.6%, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.031) and aortic distensibility (6.38 ± 1.75 vs. 5.21 ± 1.17 10&lt;jats:sup&gt;−3&lt;/jats:sup&gt; mmHg&lt;jats:sup&gt;−1&lt;/jats:sup&gt;, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.008) decreased at follow‐up. Compared with controls, PKU patients maintain reduced systolic function with lower LV EF and impaired GCS and have more markedly negative early diastolic HD pressures. A higher decrease in Phe concentration (ΔPhe) was associated with longer T1 times, ΔT1 (&lt;jats:italic&gt;β&lt;/jats:italic&gt; = −0.78, &lt;jats:italic&gt;p&lt;/jats:italic&gt; &lt; 0.001), increased ECV, ΔECV (&lt;jats:italic&gt;β&lt;/jats:italic&gt; = −0.61, &lt;jats:italic&gt;p&lt;/jats:italic&gt; = 0.016) and a decrease in systol","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"6 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cut-Off Points for Low Relative 30-s Sit-to-Stand Power and Their Associations With Adverse Health Conditions","authors":"Mikel Garcia-Aguirre, Ivan Baltasar-Fernandez, Julian Alcazar, Jose Losa-Reyna, Ana Alfaro-Acha, Ignacio Ara, Leocadio Rodriguez-Mañas, Luis M. Alegre, Francisco J. Garcia-Garcia","doi":"10.1002/jcsm.13676","DOIUrl":"https://doi.org/10.1002/jcsm.13676","url":null,"abstract":"Despite muscle power derived from the 5-rep sit-to-stand (STS) test having been demonstrated to be a valuable biomarker in older individuals, there is limited information regarding muscle power derived from the 30-s STS test, a widely used test in the clinical setting. This study aimed (i) to compare relative 30-s STS power values between older men and women, (ii) to identify cut-off points for low relative 30-s STS power, (iii) to compare the prevalence of low relative STS power between sexes and (iv) to evaluate the association of low relative 30-s STS power with adverse conditions in older people.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"55 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142940348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reference Values of Handgrip and Lower Extremity Strength for Vietnamese Men and Women: The Vietnam Osteoporosis Study","authors":"Kiet T. Do, Duy K. Hoang, Quan N. Luong, Huy G. Nguyen, An T. Do, Lan T. Ho-Pham, Tuan V. Nguyen","doi":"10.1002/jcsm.13689","DOIUrl":"https://doi.org/10.1002/jcsm.13689","url":null,"abstract":"Falls and sarcopenia are significant public health issues in Vietnam. Despite muscle strength being a critical predictor for these conditions, reference data on muscle strength within the Vietnamese population are lacking.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"45 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142940199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adeno-Associated Virus 8 and 9 Myofibre Type/Size Tropism Profiling Reveals Therapeutic Effect of Microdystrophin in Canines","authors":"Matthew J. Burke, Braiden M. Blatt, James A. Teixeira, Dennis O. Pérez-López, Yongping Yue, Xiufang Pan, Chady H. Hakim, Gang Yao, Roland W. Herzog, Dongsheng Duan","doi":"10.1002/jcsm.13681","DOIUrl":"https://doi.org/10.1002/jcsm.13681","url":null,"abstract":"Adeno-associated virus (AAV) 8 and 9 are in clinical trials for treating neuromuscular diseases such as Duchenne muscular dystrophy (DMD). Muscle consists of myofibres of different types and sizes. However, little is known about the fibre type and fibre size tropism of AAV in large mammals.","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"15 1","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142940357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}